Hospital Healthcare Europe had the pleasure of speaking with Professor of Orthopaedic Surgery, Javad Parvizi MD FRCS, who shared his thoughts on recently published international consensus meeting recommendations on venous thromboembolism and how they could impact clinical care
Please tell us about your background and institution?
Dr Parvizi originally trained for four years to be cardiovascular surgeon before moving to the US to undertake research on blood flow based in an orthopaedics laboratory. He later took up a residency in orthopaedics at the Mayo Clinic before finally moving to Philadelphia, where he has been since 2003. The Rothman Institute is part of Thomas Jefferson University and one of the largest orthopaedic practices in the world, employing over 300 physicians and surgeons. According to Dr Parvizi, this busy department performs approximately 20,000 joint replacements every year.
What exactly is a DVT and how common is it?
As Dr Parvizi explained, a DVT is a deep vein thrombosis and is a clotting problem that occurs in peoples veins and blocks the vein. He added that sometimes a clot in the lungs can stop people from breathing, leading to a fatal outcome. As he continued, both a DVT and pulmonary embolism or collectively, a venous thromboembolism (VTE), are potentially life-threatening conditions if not treated or prevented.
Dr Parvizi discussed how most VTEs happen after surgical procedures but a VTE can be an unprovoked occurrence, for instance, through air travel, sitting for a long period of time or even out of the blue. Although there is always a risk of developing a DVT after a surgical procedure, Dr Parvizi added that current thinking suggested that some patients have a genetic predisposition to develop a VTE.
How high is the risk of developing a VTE among surgical patients?
According to Dr Parvizi, the risk of developing a VTE after an orthopaedic procedure (even when accounting for other risk factors) is variable. There are two types of VTE: one below the knee (a distal DVT); and a proximal DVT, which occurs above the knee, and which is associated with a greater risk to a patient. Dr Parvizi felt that distal DVTs are common, suggesting that these can occur in 10% 15% of cases after a joint replacement but, fortunately, as he explained, these are all self-limiting, non-significant events. In fact, Dr Parvizi noted how in many cases, both clinicians and patients would be unaware that a DVT occurred and that distal DVTs invariably resolve over time. Nevertheless, the development of a pulmonary embolism (PE) is a much more serious complication, but thankfully the rate at which these develop is much lower. Dr Parvizi estimated that a PE might occur at a rate of perhaps 0.5% or even lower, although the rate of a fatal PE is even lower, perhaps 1 in 1000, although the literature suggests that the actual incidence might be lower still, at 1 in 4000.
What is the patient burden of a VTE?
In most cases where a patient develops a distal DVT after surgery, Dr Parvizi described this as a benign event that commonly resolves without any lasting problems. In contrast, a chronic VTE is more problematic and could lead to postphlebitic syndrome, where there is a blockage of the veins in the legs. As he explained, postphlebitic syndrome can result in chronic swelling, and chronic ulcerations for a patient. However, he ventured that perhaps the most important reason to assess whether a patient had a DVT was to prevent the formation of a PE. Although there is a widely held belief in the mechanical propagation theory, i.e., where a DVT literally travels from distal veins to the pulmonary circulation, Dr Parvizi said that recent work has questioned this theory and that now we think that a DVT doesnt really travel to the lungs but that a PE and DVT can develop at the same time, in a patient who is in a hypercoagulable state.
What about the healthcare and economic burden of chronic DVT?
Dr Parvizi explained how the economic impact of a chronic DVT is significant, as patients require long-term treatment, which might include hospitalisation as well as chronic use of anticoagulants. As he explained, a DVT is more likely to become chronic if a patient develops several DVTs during their procedure or when they become unresponsive to anticoagulation, and this latter effect can arise if an individual has an underlying problem with the anatomy of the veins.
Why do you think that the new guidelines were necessary?
Dr Parvizi explained how surgery induces a hypercoagulable state and which, in turn, increases the risk for the development of VTE. In the past after joint replacement, patients usually stayed in bed for a prolonged period of time. As a result, he added during the 1970s and 80s, the rates of DVT and PE were very high. In recent years, with a shift towards outpatient surgery and implementation of rapid recovery protocols, the overall incidence of VTE has declined drastically. Nevertheless, one practice from the past that has continued is the post-operative use of aggressive anticoagulation and Dr Parvizi discussed how in recent years, given the change in surgical practice and advice to avoid prolonged bed rest, the value of such aggressive anticoagulation has been called into question. A further consideration which might reduce the need for anticoagulation is greater use of intermittent compression devices. According to Dr Parvizi, due to a major shift in the delivery of care, there is now less requirement for aggressive anticoagulation. However, an important driver for change is the attendant risk associated with the use of anticoagulants, which lead to bleeding, increasing the risk for a haematoma, gross bleeding into the surgical wound or even in other organs such as the brain. Additionally, anticoagulants are both expensive and can be inconvenient to the patient, given the need for healthcare professionals to administer and/or monitor the anticoagulation drugs. Furthermore, anticoagulants are not benign drugs, and their use is associated with several other problems that include the need for re-hospitalisation, re-operation, infection and joint stiffness. In fact, Dr Parvizi noted how there have been studies showing that aggressive anticoagulation can kill patients, just like fatal PE.
Dr Parvizi acknowledged that while there are current guidelines available to help surgeons, these are subject to several limitations. For instance, most relate to hip and knee replacement and do not specifically cover other orthopedic procedures such as spine, foot and ankle, and sports surgery.In addition, Dr Parvizi mentioned how the current guidelines are totally disparate and conflicting in nature, with some recommending either for or against aggressive anticoagulation. A further limitation was that the current guidelines do not take into account the genetic or geographic predisposition for formation of VTE. As Dr Parvizi explained, For example, Asian patients are at a much lower risk of developing VTE than Caucasians. A final constraint of the currently available guidelines is that these were outdated, relating to surgical protocols that are not in effect any more, or limited themselves to reviewing literature that was mostly conducted by industry, which of course introduces some degree of bias.
Given all of the limitations, the International Consensus Meeting (ICM) gathered over 500 experts and specialists from across the world to produce updated and global guidelines using a strict and well defined process. The guideline committee reviewed the current literature, formulated relevant questions for current practice and sought consensus on these questions. Ultimately, the finished product was designed to be a global guideline for the prevention of VTE after all orthopaedic procedures.
A further advantage of the new guideline was the inclusion of physicians from other medical disciplines, such as cardiology, haematology, anaesthesia, vascular medicine and others, which enhanced the value of the guidelines and made them more applicable.
What would you say are the overarching principles and key recommendations of the guideline?
Dr Parvizi felt that the overarching principle of the guideline was the prevention and management of VTE for all orthopaedic procedures. He explained how the guideline was divided up into ten parts, one of which was a general section, with each of the subsequent sections being related to the different sub-specialities, e.g., foot and ankle, spine, etc.
The general recommendations were designed to answer questions relevant to all patients who underwent an orthopaedic surgical procedure. A total of 200 questions/issues were covered that included questions such as, are there genetic predispositions that cause VTE? or does prolonged bed rest increase the incidence of VTE? with the answer being yes to both questions.
Dr Parvizi felt that the most important recommendations were the following. Administration of aggressive anticoagulation is not necessary for the majority of patients undergoing orthopaedic procedures. He added that there is now plenty of evidence to show that intermittent compression devices work very well to prevent VTE but also that they provide additional benefits such as a reduction in post-surgical swelling of extremities, offer a better range of motion for the knee, and are associated with better patient satisfaction compared with the use of aggressive anticoagulation.
One overarching conclusion of the guideline, stemming from the available literature, is that low-dose aspirin is cost-effective and a safe modality for prevention of VTE. Studies have shown tha the use of aspirin also reduces post-operative fever, which is a common event that worries the patients and healthcare professionals. Moreover, Dr Parvizi mentioned that the use of aspirin has also been to reduce the rate of extra bone formation in the soft tissues (heterotopic ossification) and stiffness after orthopaedic procedures. He explained how the guideline recommended that aspirin should preferably be given twice a day for a period of four weeks but even two weeks of aspirin appears to be enough for most of these patients.
Overall, Dr Parvizi thinks that the new guidelines will allow clinicians to move away from the use of aggressive anticoagulants and to make greater use of intermittent compression devices and aspirin. In fact, he believes that the use of aggressive anticoagulants should now be reserved for those patients with a genetic predisposition and/or patients an extremely high risk for a VTE.
How will these guidelines impact clinical practice?
Dr Parvizi mentioned how in the US there has been a general shift over the last few years away from the use of aggressive anticoagulation towards the use of aspirin and intermittent compression devices. In fact, he quoted data from a survey of over 3000 joint surgeons showing that over 90% of surgeons now use compression devices and/or aspirin for prevention of VTE after joint replacement. While there has been an important change in practice among US surgeons, he thought that adoption of aspirin and intermittent compression devices by surgeons from other parts of the world has been slow mostly due to medico-legal concerns. A further barrier to adoption of aspirin and intermittent compression devices has been the resistance of colleagues from other specialties, such as haematology and cardiology, who might not be aware of the wealth of orthopaedic literature endorsing the use of aspirin.
He hopes that the publication of the new guidelines will provide the necessary endorsement and reassurance to the medical community to embrace a change in practice.
Are there any remaining uncertainties that might be addressed in the future?
Dr Parvizi felt that one of the benefits of developing a new guideline was that while providing robust evidence to support a change in orthopaedic practice, it also highlighted gaps in the current evidence and enabled the formulation of relevant questions that should be addressed by future research. He believes that there is a need for independent studies to compare the efficacy of low-dose aspirin with other anticoagulation agents. He mentioned one current, ongoing study (PEPPER trial) that is comparing low-dose aspirin, coumadin and factor 10 inhibitors for VTE prevention, the results of which are eagerly awaited. He noted how more studies are required to better understand the genetic mutations that predispose individuals towards having a VTE as well as more work on the role of intermittent compression devices.
Taken together, Dr Parvizi hoped that future studies will facilitate a move away from the use of expensive anticoagulants which ultimately have a huge economic impact. For example, he described how in the US alone there are over one million joint replacement procedures undertaken per year so if 92% of those patients are receiving aspirin, the anticipated cost savings would run into hundreds of millions.
Furthermore, there are a whole range of additional benefits to using aspirin including a reduction in the development of haematomas, infection risk, post-operative fever and subsequent clinical, fever work-up, less need for transfusions and a lower level of post-operative anaemia. He added that the available data suggest that aspirin is actually better than coumadin for the prevention of VTE. Ultimately, he suggested that convenience, efficacy, safety and economic benefits of aspirin are just beyond dispute now and that, over time, there will be a shift towards the use of aspirin and intermittent compression devices instead of expensive anticoagulant medications.
As for the next steps, Dr Parvizi says that the combination of the publication of the guideline in a prestigious orthopaedic journal (Journal of Bone and Joint Surgery) and future translations of the documents into numerous languages will allow effective dissemination of the work that was generated by over 500 experts. The guidelines are being discussed at various conferences and have been endorsed by a number of professional organisations, publishing the guideline on their websites. Finally, Dr Parvizi believes that it is necessary that patients who require orthopaedic procedures should no longer fear the development of a blood clot and become better informed that the changes in surgical procedures and VTE management in recent years are designed to be safer and more convenient for them.
Recommendations from the ICM-VTE: General. The ICM-VTE General Delegates. J Bone Joint Surg 2022;104(suppl 1):4162.
Go here to read the rest:
Meet the Expert: Focus on orthopaedics and VTE - Hospital Healthcare Europe
- The Ethical, Legal, and Social Issues Impacted by Modern ... - Hindawi - November 25th, 2022
- BSGM - The British Society for Genetic Medicine - November 25th, 2022
- Feasibility and ethics of using data from the Scottish newborn blood spot archive for research | Communications Medicine - Nature.com - October 7th, 2022
- Closing your health care practice: What you need to know - Medical Economics - October 7th, 2022
- Is the doctor's office heading for extinction? - Medical Economics - October 7th, 2022
- Abortion Access in the U.S.: What to Know on a State-By-State Level - Healthline - October 7th, 2022
- Students can create their own path with new ASU Online biology degree - ASU News Now - October 7th, 2022
- U.S. Releases an AI Bill Of Rights That Though Encouraging Won't Yet Move the Needle - JURIST - October 7th, 2022
- California Funds Research On Blocking Marijuana Monopolies And Protecting 'Legacy' Cannabis Strains - Marijuana Moment - October 7th, 2022
- Tips For Your Virtual Meetings With The FDA - Med Device Online - October 7th, 2022
- Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed ... - The Bakersfield Californian - October 7th, 2022
- MeiraGTx Announces the Upcoming Presentation of 15 Abstracts at the European Society of Gene and Cell Therapy (ESGCT) 2022 Annual Congress -... - October 7th, 2022
- Neighborhood deprivation and coronary heart disease in patients with bipolar disorder | Scientific Reports - Nature.com - October 7th, 2022
- Have Insurers Paid Too Much for Asbestos and Other Toxic Torts? - Claims Journal - August 19th, 2022
- Restrictive abortion laws are limiting the options parents have after receiving genetic test results, experts say - Yahoo Singapore News - August 19th, 2022
- Neurologists Discuss the Impact of Roe v. Wade Reversal on... : Neurology Today - LWW Journals - August 19th, 2022
- Abortion ruling prompts variety of reactions from states - ABC News - August 19th, 2022
- Is pregnancy possible after multiple failed IVF attempts? Can your frozen eggs and sperm be as healthy later? - The Indian Express - August 19th, 2022
- Egg Donation Process: From Application to Recovery - Healthline - July 6th, 2021
- Patent protection of mRNA vaccines and regulatory authorization - Lexology - July 6th, 2021
- EAPM: Presidency bridging conference a great success, HTA compromise agreed and data on the agenda - EU Reporter - July 6th, 2021
- Cell and Gene Therapy Drug Delivery Devices Market, 2030 - Market Opportunities in the Strong Pipeline of Cell and Gene Therapies - PRNewswire - April 4th, 2021
- Legally blind Great Falls filmmakers share their vision in national challenge - Yahoo News - April 4th, 2021
- Pfizer Announces Vaccine Is 100% Protective Against Coronavirus In Kids As Young As 12 - Yahoo News - April 4th, 2021
- How the law will change in 2021 - Lexology - February 11th, 2021
- Writing is the best medicine - The London Economic - February 11th, 2021
- Misleading glyphosate-cancer study Part 2: 'Symptom of a widespread problem'Concerns about ideological activism in science research and communications... - February 11th, 2021
- The Error of Fighting a Public Health War With Medical Weapons - WIRED - January 2nd, 2021
- Moderna, Pfizer vaccine trials were the highest of quality: vaccine expert - Yahoo Money - January 2nd, 2021
- Celebrate the new year with this New Year's Eve fireworks show in SF - Yahoo News - January 2nd, 2021
- The movie industry will strengthen again around April or May: Screenvision CEO - Yahoo Money - January 2nd, 2021
- Congress overrides Donald Trump's veto of a defense policy bill in the first such rebuke of his presidency - Yahoo News - January 2nd, 2021
- How the pandemic enabled a robot revolution - Politico - December 4th, 2020
- The mink link: How COVID-19 mutations in animals affect human health and vaccine effectiveness - The Conversation CA - November 24th, 2020
- How vaccines get made and approved in the US - The Albany Herald - November 24th, 2020
- Legalization votes bring worries of increased youth marijuana use, but evidence remains murky - AberdeenNews.com - November 24th, 2020
- Your daily 6: Third vaccine looks effective, no single 'word of the year' and Trump team called 'a national embarrassment' - Ravalli Republic - November 24th, 2020
- Cybersecurity depends on the user - Modern Diplomacy - November 20th, 2020
- It's Been Exactly One Year Since the First Case of COVID Was Found in China - Newsweek - November 20th, 2020
- Risks and benefits of an AI revolution in medicine - Harvard Gazette - November 12th, 2020
- HHS eased oversight of Covid-19 tests though it knew of problems - STAT - November 3rd, 2020
- Who won this years Nobel science prizes? - The Economist - October 8th, 2020
- Patent and Patient Rights in COVID-19: Is the Right to Exclusivity a Hamlet Question? - The Leaflet - October 8th, 2020
- FDA Oversight of Laboratory-Developed Tests Continues To Evolve - JD Supra - October 8th, 2020
- One Sperm Donor. 36 Children. A Mess of Lawsuits. - The Atlantic - September 15th, 2020
- Nebraska Medical Bill initiative blocked from entering the November ballots - Cannabis Health Insider - September 15th, 2020
- Poaching pressure mounts on jaguars, the Americas' iconic big cat - Mongabay.com - September 15th, 2020
- 'There is a sense of being robbed': Olympian Caster Semenya loses appeal on testosterone rule - The World - September 15th, 2020
- Global Microbiome Sequencing Market Growth Drivers, Demands, Business Opportunities and Demand Forecast to 2026|Clinical-Microbiomics A/S; Diversigen;... - September 5th, 2020
- Legal and Regulatory Issues in Genetic Information ... - August 31st, 2020
- The legal aspects of genetic testing - Medical Defence Union - August 31st, 2020
- Their view: Now is not the time to legalize marijuana - Wilkes Barre Times-Leader - August 31st, 2020
- Weighing up the potential benefits and harms of comprehensive full body health checks - Croakey - August 24th, 2020
- Soon, India will have its dedicated vaccine portal: ICMR - ETHealthworld.com - August 24th, 2020
- Two Families, Two Fates: When the Misdiagnosis is Child Abuse - The Marshall Project - August 22nd, 2020
- Ron Evans steals a trick from I/O, and points the way to a transformational diabetes therapy - Endpoints News - August 22nd, 2020
- Contact tracing apps may be ineffective for reducing Covid-19 spread: Study - ETHealthworld.com - August 22nd, 2020
- Global Microbiome Sequencing Market Size 2020 Review, Growth Strategy, Developing Technologies And Forecast By 2026|Charles River; CoreBiome, Inc.;... - August 19th, 2020
- Bill Jones: Working to create a culture of education - Wilkes Barre Times-Leader - August 19th, 2020
- Whats next for abortion legislation in the U.S.? - PBS NewsHour - July 10th, 2020
- No ethics when it comes to US enemies, even in the middle of a deadly pandemic - IOL - July 10th, 2020
- IML conducts the 5th National Convention on Medicine and Law - ETHealthworld.com - July 10th, 2020
- Wayne Medicine and Wayne Law professors team up to explore legal and ethical issues of wastewater monitoring for COVID-19 - The South End - June 28th, 2020
- Challenge trials aren't the answer to a speedy Covid-19 vaccine - STAT - June 28th, 2020
- Trump Suspends H-1B and Other Visas That Allow Foreigners to Work in the U.S. - The New York Times - June 24th, 2020
- Could the Montreal Neuro herald a paradigm shift in scientific research? - University Affairs - June 24th, 2020
- Next-Generation Sequencing Market: Understanding The Key Product Segments And Their Future During 2020 -2025 - 3rd Watch News - June 24th, 2020
- Meet 'Gastruloid': The First Human Embryo-like Model From Stem Cells That Could Soon Save Many Babie - Science Times - June 12th, 2020
- Could these senolytic drugs halt the spread of COVID-19? - Health Europa - June 12th, 2020
- The coronavirus vaccine frontrunners have emerged. Here's where they stand - BioPharma Dive - June 12th, 2020
- Regulating marine genetic resources in areas beyond national jurisdiction - The Daily Star - June 12th, 2020
- Vaccines have saved millions of lives, but history shows missteps can prove deadly - The Boston Globe - June 12th, 2020
- Quitting smoking might reduce severe coronavirus infection risk: Study - ETHealthworld.com - May 23rd, 2020
- Where Taiwan Can Make the Most of AI - Taiwan - Taiwan Business TOPICS - May 23rd, 2020
- WHO and IOC team up to improve health through sport - ETHealthworld.com - May 18th, 2020
- The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -... - May 15th, 2020
- Medical School: Who gets in and why - Stuff.co.nz - May 15th, 2020
- Wilson Ighodalo: Addressing Substance Abuse as a Public Health Problem - THISDAY Newspapers - May 15th, 2020
- The Falsehoods of the 'Plandemic' Video - FactCheck.org - May 14th, 2020
- Robert Youngjohns, Chairman of the Board, ABBYY - Interview Series - Unite.AI - May 14th, 2020